Table 3. Multivariate analysis for each bacteria.
Factor |
a. MSSA |
b. Alpha-hemolytic streptococci |
||||
---|---|---|---|---|---|---|
Adjusted odds ratio | 95% CI | P-value | Adjusted odds ratio | 95% CI | P-value | |
Age | 1.007 | 0.975–1.041 | 0.671 | 1.049 | 1.001–1.100 | 0.044* |
Sex (male) | 0.803 | 0.432–1.494 | 0.489 | 1.287 | 0.613–2.704 | 0.505 |
Hypertension | 0.971 | 0.513–1.837 | 0.928 | 1.473 | 0.665–3.261 | 0.340 |
Diabetes | 1.673 | 0.683–4.096 | 0.260 | 2.189 | 0.972–4.930 | 0.059 |
Oral steroids | 0.648 | 0.147–2.852 | 0.566 | 2.665 | 0.582–12.200 | 0.207 |
Lacrimal duct obstruction | 0.703 | 0.158–3.116 | 0.642 | 2.227 | 0.485–10.231 | 0.303 |
Glaucoma eye drops | 0.685 | 0.274–1.709 | 0.417 | 1.898 | 0.677–5.325 | 0.223 |
Visit history to ophthalmic facilities | 0.954 | 0.465–1.957 | 0.898 | 0.749 | 0.328–1.714 | 0.494 |
Surgical history in other departments | 1.089 | 0.326–3.639 | 0.889 | 0.349 | 0.046–2.621 | 0.306 |
c. Enterococcus faecalis |
d.Gram-negative bacilli |
|||||
Adjusted odds ratio | 95% CI | P-value | Adjusted odds ratio | 95% CI | P-value | |
Age | 1.077 | 1.029–1.128 | 0.002** | 1.026 | 0.991–1.062 | 0.144 |
Sex (male) | 0.795 | 0.387–1.631 | 0.531 | 1.098 | 0.609–1.981 | 0.756 |
Hypertension | 0.891 | 0.443–1.793 | 0.747 | 1.355 | 0.735–2.497 | 0.330 |
Diabetes | 1.682 | 0.753–3.758 | 0.205 | 1.496 | 0.755–2.967 | 0.249 |
Oral steroids | 0.882 | 0.114–6.806 | 0.904 | 3.294 | 1.071–10.134 | 0.038* |
Lacrimal duct obstruction | 1.468 | 0.326–6.610 | 0.617 | 4.745 | 1.778–12.665 | 0.002** |
Glaucoma eye drops | 0.772 | 0.225–2.651 | 0.680 | 0.752 | 0.258–2.188 | 0.600 |
Visit history to ophthalmic facilities | 0.954 | 0.444–2.050 | 0.903 | 1.074 | 0.553–2.086 | 0.834 |
Surgical history in other departments | 1.372 | 0.464–4.061 | 0.567 | 1.604 | 0.649–3.964 | 0.306 |
e. Corynebacterium species |
f. MS-CNS |
|||||
Adjusted odds ratio | 95% CI | P-value | Adjusted odds ratio | 95% CI | P-value | |
Age | 1.042 | 1.027–1.057 | 0.000** | 0.993 | 0.978–1.008 | 0.355 |
Sex (male) | 1.410 | 1.080–1.841 | 0.012* | 1.580 | 1.163–2.147 | 0.003** |
Hypertension | 1.180 | 0.901–1.545 | 0.230 | 1.114 | 0.810–1.533 | 0.507 |
Diabetes | 0.948 | 0.684–1.313 | 0.747 | 1.125 | 0.777–1.630 | 0.532 |
Oral steroids | 1.121 | 0.525–2.392 | 0.768 | 0.725 | 0.270–1.946 | 0.523 |
Lacrimal duct obstruction | 1.196 | 0.570–2.509 | 0.636 | 0.951 | 0.380–2.382 | 0.915 |
Glaucoma eye drops | 0.457 | 0.288–0.727 | 0.001** | 0.621 | 0.346–1.114 | 0.110 |
Visit history to ophthalmic facilities | 1.100 | 0.818–1.479 | 0.530 | 0.935 | 0.665–1.316 | 0.701 |
Surgical history in other departments | 1.148 | 0.705–1.868 | 0.579 | 0.495 | 0.248–0.988 | 0.046* |
g. MR-CNS |
||||||
Adjusted odds ratio | 95% CI | P-value | ||||
Age | 1.004 | 0.984–1.025 | 0.667 | |||
Sex (male) | 0.970 | 0.660–1.425 | 0.877 | |||
Hypertension | 1.010 | 0.683–1.492 | 0.961 | |||
Diabetes | 1.111 | 0.699–1.766 | 0.656 | |||
Oral steroids | 3.651 | 1.628–8.185 | 0.002** | |||
Lacrimal duct obstruction | 1.922 | 0.788–4.685 | 0.151 | |||
Glaucoma eye drops | 1.209 | 0.671–2.178 | 0.528 | |||
Visit history to ophthalmic facilities | 1.650 | 1.032–2.639 | 0.037* | |||
Surgical history in other departments | 2.800 | 1.592–4.923 | 0.000** |
Logistic regression analysis.
*P<0.05, **P<0.01.